NFE2L2 and neoplasm: Inhibition of tumor growth with lower DOX dosage, reduced cardiotoxicity upon activation of Nrf2; Reduction in tumor volume, increase in cytotoxic CD8+T cells, decrease in MDSC population with subsequent immunosuppression.